english.prescrire.org > Spotlight > 100 most recent > European fines for anti-generic strategies: when will penalties get tougher?

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

European fines for anti-generic strategies: when will penalties get tougher?

 Outlook  Anti-competitive strategies are designed to delay the market introduction of copies (generics and biosimilars) of originator drugs, which are a major source of savings for third-party payers. Their significant impact on national finances is only marginally mitigated by the amounts of the fines imposed on pharmaceutical companies, which are a pittance in comparison to their revenues.
Full article available for download by subscribers

 ©Prescrire 1 June 2026

Source: "European fines for anti-generic strategies: when will penalties get tougher?" Prescrire Int 2026; 35 (282): 164-166. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:
 
"New dose strength
of the originator Eylea°
blocks substitution"
Prescrire Int 2026;
35 (282): 158.
Subscribers only
"Anti-competitive practices:
a very “inventive”
pharmaceutical industry"
Prescrire Int 2025;
34 (273): 223. 
Subscribers only